19 May 2013
Keywords: new, data, idenix, telbivudine, promising, one-year, phase
Article | 26 April 2004
Promising one-year data from a Phase IIb trial of Idenix Pharmaceuticals' antiviral telbivudine were reported at the annual
meeting of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 April 2004
17 May 2013
© 2013 thepharmaletter.com